España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
NLS Pharmaceutics
NLSPW
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.0138
-0.00160
-10.39%
After Hours: Feb 11, 4:33 PM EDT
Get Report
Comment
NLS Pharmaceutics (NLSPW) Forecast
News
Earnings
NLS Pharmaceutics (NLSPW) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for NLS Pharmaceutics (NASDAQ:NLSPW) Stock
NLS Pharmaceutics Stock (NASDAQ: NLSPW)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 04, 2024
NLS Pharmaceutics Announces Pricing Of A Priv...
Benzinga Newsdesk
Friday, September 27, 2024
Trading Halt: Halt status updated at 9:00:00 ...
Benzinga Newsdesk
Thursday, September 26, 2024
Trading Halt: Halted at 7:50:00 p.m. ET - Tra...
Benzinga Newsdesk
Wednesday, September 25, 2024
NLS Pharmaceutics Ltd. Announces Expected Imp...
Benzinga Newsdesk
Monday, July 29, 2024
Trading Halt: Halt status updated at 7:30:00 ...
Benzinga Newsdesk
Trading Halt: Halted at 6:56:51 a.m. ET - Tra...
Benzinga Newsdesk
Tuesday, June 11, 2024
NLS Pharmaceutics Announces Publication Of Ne...
Benzinga Newsdesk
Tuesday, May 28, 2024
NLS Pharmaceutics Reports Results From Study ...
Benzinga Newsdesk
Thursday, October 12, 2023
NLS Pharmaceutics Announces Company Update On...
Benzinga Newsdesk
Monday, August 28, 2023
NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter
Kenneth Adams
-
Sponsored
Thursday, December 22, 2022
NLS Pharmaceutics CEO Issues Letter To Shareh...
Benzinga Newsdesk
Wednesday, November 23, 2022
NLS Pharmaceutics Announces Launch Of Paid Fo...
Benzinga Newsdesk
Wednesday, September 29, 2021
From BZ's Small Cap Healthcare Conference: NLS Pharmaceuticals Co-Founder & CEO, Alexander Zwyer Begins Speaking
Zoltan Suranyi
Thursday, August 19, 2021
EXCLUSIVE: NLS Pharma CEO Comments On Notice ...
Zoltan Suranyi
Thursday, July 15, 2021
NLS Pharmaceutics Shares Move Higher; Co Anno...
Benzinga Newsdesk
